255 related articles for article (PubMed ID: 26353850)
1. IMP3 Is Strongly Expressed in Malignant Phyllodes Tumors of the Breast: An Immunohistochemical Study.
Bellezza G; Prosperi E; Del Sordo R; Colella R; Rulli A; Sidoni A
Int J Surg Pathol; 2016 Feb; 24(1):37-42. PubMed ID: 26353850
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor II messenger RNA-binding protein-3 is an indicator of malignant phyllodes tumor of the breast.
Takizawa K; Yamamoto H; Taguchi K; Ohno S; Tokunaga E; Yamashita N; Kubo M; Nakamura M; Oda Y
Hum Pathol; 2016 Sep; 55():30-8. PubMed ID: 27137988
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitin carboxy-terminal hydrolase L1 may be involved in the development of mammary phyllodes tumors.
Lien HC; Wang CC; Huang CS; Yang YW; Kuo WH; Yao YT
Virchows Arch; 2013 Feb; 462(2):155-61. PubMed ID: 23291960
[TBL] [Abstract][Full Text] [Related]
4. Expression of lymphoid enhancer-binding factor 1 in breast fibroepithelial lesions.
Chen PH; Bossuyt V; Reisenbichler E
Hum Pathol; 2021 Feb; 108():68-75. PubMed ID: 33245988
[TBL] [Abstract][Full Text] [Related]
5. Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast.
Vidal M; Peg V; Galván P; Tres A; Cortés J; Ramón y Cajal S; Rubio IT; Prat A
Mol Oncol; 2015 Jun; 9(6):1081-90. PubMed ID: 25687451
[TBL] [Abstract][Full Text] [Related]
6. Phyllodes tumor of the breast: role of CD10 in predicting metastasis.
Al-Masri M; Darwazeh G; Sawalhi S; Mughrabi A; Sughayer M; Al-Shatti M
Ann Surg Oncol; 2012 Apr; 19(4):1181-4. PubMed ID: 22006372
[TBL] [Abstract][Full Text] [Related]
7. Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases.
Esposito NN; Mohan D; Brufsky A; Lin Y; Kapali M; Dabbs DJ
Arch Pathol Lab Med; 2006 Oct; 130(10):1516-21. PubMed ID: 17090194
[TBL] [Abstract][Full Text] [Related]
8. Stromal matrix metalloproteinase-14 expression correlates with the grade and biological behavior of mammary phyllodes tumors.
Kim GE; Kim JH; Lee KH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Park MH; Yoon JH
Appl Immunohistochem Mol Morphol; 2012 May; 20(3):298-303. PubMed ID: 22505012
[TBL] [Abstract][Full Text] [Related]
9. Phyllodes Tumor of the Breast: Histopathologic Features, Differential Diagnosis, and Molecular/Genetic Updates.
Zhang Y; Kleer CG
Arch Pathol Lab Med; 2016 Jul; 140(7):665-71. PubMed ID: 27362571
[TBL] [Abstract][Full Text] [Related]
10. Phyllodes tumors and fibroadenoma common beginning and different ending.
Oprić S; Oprić D; Gugić D; Granić M
Coll Antropol; 2012 Mar; 36(1):235-41. PubMed ID: 22816226
[TBL] [Abstract][Full Text] [Related]
11. Expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors.
Cha YJ; Koo JS
PLoS One; 2020; 15(8):e0238466. PubMed ID: 32857809
[TBL] [Abstract][Full Text] [Related]
12. Fibroepithelial lesions; The WHO spectrum.
Krings G; Bean GR; Chen YY
Semin Diagn Pathol; 2017 Sep; 34(5):438-452. PubMed ID: 28688536
[TBL] [Abstract][Full Text] [Related]
13. Collagen type III α1 as a useful diagnostic immunohistochemical marker for fibroepithelial lesions of the breast.
Wang Y; Resnick MB; Lu S; Hui Y; Brodsky AS; Yang D; Yakirevich E; Wang L
Hum Pathol; 2016 Nov; 57():176-181. PubMed ID: 27498063
[TBL] [Abstract][Full Text] [Related]
14. CD10, actin, and vimentin expression in breast phyllodes tumors correlates with tumor grades of the WHO grading system.
Tsai WC; Jin JS; Yu JC; Sheu LF
Int J Surg Pathol; 2006 Apr; 14(2):127-31. PubMed ID: 16703173
[TBL] [Abstract][Full Text] [Related]
15. Phyllodes tumours of the breast: the role of CD34, vascular endothelial growth factor and β-catenin in histological grading and clinical outcome.
Ho SK; Thike AA; Cheok PY; Tse GM; Tan PH
Histopathology; 2013 Sep; 63(3):393-406. PubMed ID: 23772632
[TBL] [Abstract][Full Text] [Related]
16. Comparison of clinical characteristics between benign borderline and malignant phyllodes tumors of the breast.
Wang H; Wang X; Wang CF
Asian Pac J Cancer Prev; 2014; 15(24):10791-5. PubMed ID: 25605178
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor-beta is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast.
Sapino A; Bosco M; Cassoni P; Castellano I; Arisio R; Cserni G; Dei Tos AP; Fortunati N; Catalano MG; Bussolati G
Mod Pathol; 2006 Apr; 19(4):599-606. PubMed ID: 16554735
[TBL] [Abstract][Full Text] [Related]
18. Stromal cells in phyllodes tumors of the breast are enriched for EZH2 and stem cell marker expression.
Zhang Y; Liss AL; Chung E; Pierce LJ; Kleer CG
Breast Cancer Res Treat; 2016 Jul; 158(1):21-28. PubMed ID: 27290698
[TBL] [Abstract][Full Text] [Related]
19. Phyllodes tumour of the breast: immunohistochemical study of 37 tumours using MIB1 antibody.
Kocová L; Skálová A; Fakan F; Rousarová M
Pathol Res Pract; 1998; 194(2):97-104. PubMed ID: 9584322
[TBL] [Abstract][Full Text] [Related]
20. Malignant transformation of breast fibroadenoma to malignant phyllodes tumor: long-term outcome of 36 malignant phyllodes tumors.
Abe M; Miyata S; Nishimura S; Iijima K; Makita M; Akiyama F; Iwase T
Breast Cancer; 2011 Oct; 18(4):268-72. PubMed ID: 22121516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
